On Jan. 31, the CDC's chief science officer sent an internal email that informed the agency’s division heads that all papers ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Baxter President and CEO José Almeida has announced his retirement, effective immediately, after nearly a decade of leading ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology ...

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, complet | Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...

After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...